Pharma BD Deal Intelligence
Novo Nordisk and Dicerna Pharmaceuticals entered a multi-target RNAi therapeutics collaboration using Dicerna's proprietary GalXC (sGalNAc-siRNA) platform for liver-related cardiometabolic diseases. Novo paid $175M upfront plus $25M/year for three years, with up to $357.5M in milestones per target across 30+ targets. Dicerna led discovery through clinical candidate selection; Novo led subsequent clinical development. Novo later acquired Dicerna outright in 2021 for $3.3B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (this deal) | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2019 deals · Novo Nordisk A/S deals · Cardiovascular deals